

**HEPARINEX CHIEF SCIENTIST NAMED  
OU COLLEGE OF MEDICINE RESEARCH SCHOLAR**

Oklahoma City, OK and Austin, TX—January 25, 2007— Emergent Technologies Inc. (ETI) of Austin announced today that Dr. Paul DeAngelis, Chief Scientist of Heparinex, L.L.C., has been named the OU College of Medicine Research Scholar for 2006. He was honored at the University of Oklahoma College of Medicine Research Fund Dinner held January 25, 2007. Dr. DeAngelis is a professor at the OU College of Medicine in Oklahoma City. Hyalose, L.L.C. is an ETI portfolio company. DeAngelis also serves as Chief Scientist for two sister companies, Choncept, L.L.C. and Hyalose, L.L.C. which are also based in Oklahoma City.

Mr. Tommy Harlan, CEO of Heparinex and Chairman, CEO, and President of ETI commented, “We are delighted that OU has recognized the accomplishments and contributions that Dr. DeAngelis has made in the field of glycobiology.” John Hoopingarner, COO of Heparinex and Executive VP of ETI, added, “Dr. DeAngelis has won three OCAST OARS grants and several NIH grants which have sustained his academic research efforts and development activities in the companies he serves and co-founded with ETI between 2000 and 2002. He has also been instrumental in grooming his promising doctoral students for positions within the ETI companies after graduation.”

ETI formed Heparinex in its second investment fund, Emergent Technologies Oklahoma, L.P. in 2002, and manages it and its sister companies from its Austin, Texas, headquarters. Heparinex licensed the rights to technology patented by Dr. DeAngelis related to the production of heparosan which is a biopolymer used in formulations for anti-coagulants and anti-inflammatory applications. Visit its website at [www.heparinex.com](http://www.heparinex.com)

Harlan founded ETI in 1989 and launched its first venture capital fund in 1998. ETI specializes in forming, funding, commercializing, and managing biotech companies for the purpose of converting institutional and university-based technology into high-return ventures. Visit its website at [www.emergenttechnologies.com](http://www.emergenttechnologies.com)

Contact: Mr. John Hoopingarner  
2508 Ashley Worth Blvd., Suite 200  
Austin, TX 78738  
(T) 512/263-3232 Ext. 205      (F) 512/263-3236

KEYWORD: Austin, Oklahoma City

INDUSTRY KEYWORD: OCAST, MEDICAL DEVICE, ANTI-COAGULANT,  
BIOPOLYMER, GLYCOBIOLOGY, UNIVERSITY OF OKLAHOMA